DX方案与XELOX方案一线治疗晚期胃癌疗效比较

目的 观察DX方案（多西紫杉醇联合卡培他滨）与XELOX方案（草酸铂联合卡培他滨）治疗晚期胃癌的客观疗效和毒性反应。方法DX方案组21例晚期胃癌患者接受多西紫杉醇75mg／m^2d1卡培他滨每日1700mg／m^2，分2次口服，dl—14，21d为1周期，疗程2—6周期。XELOX方案组20例晚期胃癌患者接受奥沙利铂130mg／m^2dl，卡培他滨每日1700mg／m^2，分2次口服，dl—d14，21d为1周期，疗程2—6周期。结果DX方案组总有效率为52．4％常见的毒性反应为中性粒细胞减少性发热、脱发、腹泻及口腔黏膜炎发生率较高；XELOX方案组总有效率为50．0％，常见的毒性反应为手足综合征和周围神经毒性反应等。结论DX方案和XELOX方案均为治疗进展期胃癌较好的方案，其中XELOX方案副反应较低可提高患者的生存质量，毒副作用能耐受，更适合老年体弱病人。

Clinical comparison of docetaxel/capecitabine and oxaliplatin/capecitabine in treating advanced gastric cancer

Objective To evaluate the objective response rate,time to progression（TTP）and toxicity between Docetaxel/Capecitabine and Oxaliplatin/Capecitabine in the treatment of advanced gastric cancer. Methods 21 patients with advanced gastric cancer were administrated with Docetaxel 75 mg/m^2 （dl）, Capecitabine 1700 mg/m^2/d divided in two daily doses given from dl to d14. The cycles were repeated every 21 days. All patients received two to six cycles. The other 20 patients with advanced gastric cancer were administrated with Oxaliplatin 130 mg/m^2, （dl）combined Capecitabine 1 700 mg/m^2/d divided in two daily doses given from dl to d14. All patients received two to six cycles. The treatment was finished after 2 recycles. Results The total response rate in Docetaxel/Capecitabine was 52.4 %, the most common adverse effects were febrile neutropeni, neutropenia, alopecia, diarrhea and inflammation of oral mucosa. The response rate in XELOX was 50.0 %, the most common adverse effects were hand foot syndrome and peripheral neuropathy. Conclusion The Oxaliplatin/Capecitabine regimen offers a better therapeutic option in patients with advanced gastric cancer.